Roivant Sciences (ROIV) News Today $10.72 +0.01 (+0.05%) As of 02:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells 227,500 Shares of StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.February 19 at 11:35 PM | marketbeat.comRakhi Kumar Sells 227,500 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockFebruary 19 at 4:15 AM | insidertrades.comEric Venker Sells 218,041 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 218,041 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the sale, the chief operating officer now directly owns 896,869 shares of the company's stock, valued at $9,345,374.98. This represents a 19.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.February 15, 2025 | marketbeat.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 218,041 Shares of StockFebruary 15, 2025 | insidertrades.comHC Wainwright Reiterates "Buy" Rating for Roivant Sciences (NASDAQ:ROIV)February 13, 2025 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Roivant Sciences (NASDAQ:ROIV)HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday.February 11, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Q3 2024 Earnings Call TranscriptFebruary 11, 2025 | msn.comRoivant Sciences (ROIV) Receives a Hold from Bank of America SecuritiesFebruary 11, 2025 | markets.businessinsider.comRoivant Sciences price target lowered to $12 from $13 at BofAFebruary 11, 2025 | markets.businessinsider.comRoivant Sciences: Earnings Reveal Strategic Clinical AdvancesFebruary 10, 2025 | tipranks.comRoivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash positionFebruary 10, 2025 | msn.comRoivant Sciences Ltd. 2024 Q3 - Results - Earnings Call PresentationFebruary 10, 2025 | seekingalpha.comRoivant Sciences (NASDAQ:ROIV) Shares Gap Up After Strong EarningsRoivant Sciences (NASDAQ:ROIV) Shares Gap Up on Better-Than-Expected EarningsFebruary 10, 2025 | marketbeat.comRoivant Sciences Tops Q3 ExpectationsFebruary 10, 2025 | fool.comLe BPA de Roivant Sciences a dépassé les attentes de 0,48$, le CA a surpassé les prévisionsFebruary 10, 2025 | fr.investing.com6ROIV : Roivant Sciences Q3 Earnings AssessmentFebruary 10, 2025 | benzinga.comRoivant Sciences reports consolidated cash of $5.2B as of December 31February 10, 2025 | markets.businessinsider.comRoivant Sciences reports Q3 EPS (22c), consensus (24c)February 10, 2025 | markets.businessinsider.comRoivant Sciences (NASDAQ:ROIV) Posts Earnings Results, Beats Expectations By $0.04 EPSRoivant Sciences (NASDAQ:ROIV - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%.February 10, 2025 | marketbeat.comRoivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business UpdateFebruary 10, 2025 | globenewswire.comElevate Capital Advisors LLC Invests $2.12 Million in Roivant Sciences Ltd. (NASDAQ:ROIV)Elevate Capital Advisors LLC purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 178,853 shares of the company's stock, valued atFebruary 10, 2025 | marketbeat.comDAVENPORT & Co LLC Has $1.89 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)DAVENPORT & Co LLC lessened its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 38.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 160,140 shares of the company's stock after selFebruary 6, 2025 | marketbeat.comZest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch CareFebruary 3, 2025 | globenewswire.comRoivant Sciences (ROIV) Expected to Announce Quarterly Earnings on MondayRoivant Sciences (NASDAQ:ROIV) will be releasing earnings before the market opens on Monday, February 10, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=462411)February 3, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Upgraded to "Strong-Buy" at Cantor FitzgeraldCantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a report on Thursday.February 1, 2025 | marketbeat.comRoivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025January 29, 2025 | globenewswire.comTrump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching (ROIV)President Trump's cabinet is comprised of millionaires, billionaires and leaders in business who founded or led public companies. Here's the TRUMP index stocks.January 28, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy rJanuary 28, 2025 | marketbeat.com99,500 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Zweig DiMenna Associates LLCZweig DiMenna Associates LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 99,500 shares of the companJanuary 24, 2025 | marketbeat.comRoivant Sciences : le président Eric Venker vend des actions pour 1,13 million de dollarsJanuary 23, 2025 | fr.investing.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 100,000 Shares of StockJanuary 23, 2025 | insidertrades.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,128,000.00 in StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the transaction, the chief operating officer now directly owns 732,294 shares in the company, valued at approximately $8,260,276.32. This represents a 12.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.January 22, 2025 | marketbeat.comRoivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV)Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) saw some unusual options trading on Friday. Investors purchased 32,948 call options on the company. This is an increase of approximately 1,371% compared to the typical daily volume of 2,240 call options.January 17, 2025 | marketbeat.comRoivant Sciences augmente sa participation dans Immunovant avec un achat de 336,9 millions de dollarsJanuary 16, 2025 | fr.investing.comRoivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million eachJanuary 16, 2025 | finance.yahoo.comRoivant Sciences Ltd. (NASDAQ:ROIV) Director Acquires $336,900,200.00 in StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Sciences Ltd. Roivant purchased 16,845,010 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The stock was bought at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the purchase, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.January 15, 2025 | marketbeat.comIs Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20?January 12, 2025 | insidermonkey.comNordea Investment Management AB Has $3.31 Million Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)Nordea Investment Management AB lifted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 22.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 282,834 shares of the company's sJanuary 11, 2025 | marketbeat.comWhy Ramaswamy Says America Needs a Cultural Shift Towards Excellence for the Sake of US StudentsJanuary 7, 2025 | msn.comWhy Ramaswamy Says America Needs a Cultural Shift Toward Excellence for the Sake of US StudentsJanuary 6, 2025 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven haJanuary 3, 2025 | marketbeat.comEric Venker Sells 177,704 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockJanuary 1, 2025 | insidertrades.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $2,050,704.16 in StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 177,704 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $11.54, for a total transaction of $2,050,704.16. Following the completion of the transaction, the chief operating officer now owns 740,976 shares in the company, valued at $8,550,863.04. This trade represents a 19.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.December 31, 2024 | marketbeat.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 176,900 Shares of StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 176,900 shares of the firm's stock in a transaction on Friday, December 27th. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00. Following the completion of the sale, the chief operating officer now directly owns 668,680 shares of the company's stock, valued at approximately $7,903,797.60. This trade represents a 20.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.December 31, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Principal Financial Group Inc.Principal Financial Group Inc. lowered its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 12.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,009,758 shares of the company's sDecember 30, 2024 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,149,000.00 in StockDecember 27, 2024 | insidertrades.comLe directeur des investissements de Roivant Sciences, Mayukh Sukhatme, vend pour 10,6 millions de dollars d'actionsDecember 27, 2024 | fr.investing.comLe président de Roivant Sciences, Eric Venker, vend pour 1,15 million de dollars d'actionsDecember 27, 2024 | fr.investing.comEric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00. Following the completion of the sale, the chief operating officer now directly owns 595,580 shares in the company, valued at approximately $6,843,214.20. This trade represents a 14.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.December 26, 2024 | marketbeat.comMayukh Sukhatme Sells 185,946 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockRoivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CIO Mayukh Sukhatme sold 185,946 shares of the business's stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total value of $2,231,352.00. Following the transaction, the executive now owns 18,836,547 shares of the company's stock, valued at approximately $226,038,564. The trade was a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.December 26, 2024 | marketbeat.com Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address ROIV Media Mentions By Week ROIV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ROIV News Sentiment▼0.550.60▲Average Medical News Sentiment ROIV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ROIV Articles This Week▼65▲ROIV Articles Average Week Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTX News Today TEVA News Today SMMT News Today GMAB News Today ITCI News Today VTRS News Today MRNA News Today RDY News Today PCVX News Today SRPT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ROIV) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ROIV Stock Alerts